nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-240-8-195-198nogr-3436Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL CASESРазвития фиброза печени на фоне сахарного диабета 1 типаA clinical case of liver fibrosis in type 1 diabetes mellitushttps://orcid.org/0009-0006-1921-4756ВласовА. В.VlasovA. V.adonaisabaoth@mail.ruhttps://orcid.org/0000-0003-3003-6883ОськинаА. В.OskinaA. V.noemail@neicon.ruhttps://orcid.org/0009-0008-7934-6544КанаевА. М.KanaevA. M.noemail@neicon.ruГУЗ «Саратовская городская поликлиника № 20»; ГБУЗ МО «Домодедовская больница»РоссияSaratov City Polyclinic No. 20"; State budgetary institution of health care of the Moscow region "Domodedovo hospital"Russian Federation20250208202608195198Copyright © Власов А.В., Оськина А.В., Канаев А.М., 20262026Власов А.В., Оськина А.В., Канаев А.М.Vlasov A.V., Oskina A.V., Kanaev A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/3436

Гликогеновая гепатопатия является редко встречаемым и часто недиагностируемым состоянием, которое преимущественно связано с сахарным диабетом 1 типа. В статье представлено клиническое наблюдение пациентки с фиброзом печени на фоне неконтролируемого сахарного диабета 1 типа. При обследовании выявлены гипергликемия, высокий HbA1c (7,28%) и стойкое повышение трансаминаз (АЛТ до 248,9 Ед/л, АСТ до 155,0 Ед/л). Фиброэластометрия и биопсия подтвердили фиброз (F0-F4 по METAVIR) и стеатогепатит минимальной активности. Обсуждается роль нарушений обмена глюкозы и гликогена в развитии гликогеновой гепатопатии и фиброза. После оптимизации инсулинотерапии и достижении гликемического контроля отмечено снижение фиброза и трансаминаз. Для предотвращения прогрессирования состояния рекомендовано поддержание целевого уровня HbA1c, соблюдение диеты и регулярный мониторинг функции печени.

Glycogenic hepatopathy is a rare and often underdiagnosed condition predominantly associated with type 1 diabetes mellitus. This article presents a clinical case of a female patient with liver fibrosis in the context of uncontrolled type 1 diabetes. Examination revealed hyperglycemia, elevated HbA1c (7.28%), and persistently increased transaminase levels (ALT up to 248.9 U/L, AST up to 155.0 U/L). Fibroelastometry and liver biopsy confirmed fibrosis (F0-F4 according to the METAVIR score) and minimally active steatohepatitis. The role of glucose and glycogen metabolism disorders in the development of glycogenic hepatopathy and fibrosis is discussed. Following the optimization of insulin therapy, a decrease in both fibrosis and transaminase levels was observed. Maintaining target HbA1c levels, adhering to dietary recommendations, and regular monitoring of liver function are recommended to prevent disease progression.

Фиброз печениГликогеновая гепатопатияСахарный диабетГликогенГлюкозаСтеатогепатитБиопсияИнсулинотерапияГипергликемияФиброэластометрияLiver fibrosisglycogenic hepatopathyDiabetes mellitusGlycogenGlucoseSteatohepatitisBiopsyInsulin therapyHyperglycemiaFibroelastometryReferencesSundaram S, Alkhouri N, Cikach F. et al. Glycogenic Hepatopathy in Type 1 Diabetes: An Underrecognized Complication. Diabetes Care. 2013;36(1): e6-e6. doi: 10.2337/dc12-1568.Sundaram S, Alkhouri N, Cikach F. et al. Glycogenic Hepatopathy in Type 1 Diabetes: An Underrecognized Complication. Diabetes Care. 2013;36(1): e6-e6. doi: 10.2337/dc12-1568.American Diabetes Association. Standards of Medical Care in Diabetes-2023. Diabetes Care, 2023; 46(Suppl.1): S1-S274. doi: 10.2337/dc23-S002.American Diabetes Association. Standards of Medical Care in Diabetes-2023. Diabetes Care, 2023; 46(Suppl.1): S1-S274. doi: 10.2337/dc23-S002.Cusi K., Chang Z. L., Harrison S. et al. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care, 2021; 44(2): 399-407. doi: 10.2337/dc20-199.Cusi K., Chang Z. L., Harrison S. et al. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care, 2021; 44(2): 399-407. doi: 10.2337/dc20-199.Moore M. C., Coate K. C., Winnick J. J., An Z., Cherrington A. D. Regulation of hepatic glucose uptake and storage in vivo. Advances in Nutrition. 2012 May 1;3(3):286-94. doi: 10.3945/an.112.002089.Moore M. C., Coate K. C., Winnick J. J., An Z., Cherrington A. D. Regulation of hepatic glucose uptake and storage in vivo. Advances in Nutrition. 2012 May 1;3(3):286-94. doi: 10.3945/an.112.002089.Wan Y., Hu Z., Liu Q. et al. Liver fibrosis alters the molecular structures of hepatic glycogen. Carbohydrate Polymers. 2022 Feb 15;278:118991. doi: 10.1016/j.carbpol.2021.Wan Y., Hu Z., Liu Q. et al. Liver fibrosis alters the molecular structures of hepatic glycogen. Carbohydrate Polymers. 2022 Feb 15;278:118991. doi: 10.1016/j.carbpol.2021.European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology. 2016; 64:1388-1402. doi: 10.1016/j.jhep.2015.11.004.European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology. 2016; 64:1388-1402. doi: 10.1016/j.jhep.2015.11.004.Chalasani N., Younossi Z., Lavine J. E. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328-357. doi: 10.1002/hep.29367.Chalasani N., Younossi Z., Lavine J. E. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328-357. doi: 10.1002/hep.29367.

The authors declare that there are no conflicts of interest present.